NFKB1 and cancer: In patients with NSCLC, studies have shown that the NF-κB pathway induces PD-L1 expression leading to immune evasion of cancer cells, and thus the combination of NF-κB inhibitors with ICIs appears to be useful for the treatment of NSCLC (160).